Excellent
Fully Aligned
Patient Risk:
Low
Summary
The AI-generated claim is fully supported by the provided OPZELURA label excerpts for serious infections (including TB considerations, opportunistic infections, and viral reactivation/herpes zoster), avoidance in active serious infection, interruption/discontinuation for serious infection, and trial-reported infections (upper respiratory/ear infections and herpes zoster). No contradictions or material omissions are evident in the supplied text.
Category Scores
Accurate Statements
OPZELURA labeling warns patients may develop serious infections, including opportunistic infections, and advises avoidance in patients with an active, serious infection.
Section 5.1 (Serious Infections): serious and sometimes fatal infections reported; avoid use in patients with an active, serious infection (including localized infections).
OPZELURA labeling advises considering TB risk (including evaluation/monitoring considerations) and notes TB-related considerations during use.
Section 5.1 (Serious Infections): tuberculosis—no active TB in OPZELURA trials; consider evaluating patients for latent and active TB; monitor for signs/symptoms of TB during use.
OPZELURA labeling warns about viral reactivation and herpes virus reactivation (e.g., herpes zoster), and advises interrupting OPZELURA if herpes zoster develops.
Section 5.1 (Serious Infections): Viral Reactivation—herpes virus reactivation including herpes zoster; consider interrupting OPZELURA until episode resolves if herpes zoster occurs.
OPZELURA labeling instructs to closely monitor for infection signs/symptoms during and after treatment and to interrupt OPZELURA if serious/opportunistic infection or sepsis occurs, not to resume until infection is controlled.
Section 5.1 (Serious Infections): closely monitor; interrupt OPZELURA if serious infection/opportunistic infection/sepsis; do not resume until infection is controlled.
In trial adverse reactions, infections include upper respiratory/ear infection and herpes zoster.
Section 6 (Adverse Reactions): atopic dermatitis trials included infections such as nasopharyngitis/bronchitis/ear infection; pediatric trials included upper respiratory tract infection and COVID-19; herpes zoster reported.
Unsupported Statements
Contradictions
Important Omissions
The claim does not mention malignancy, MACE, mortality, or thrombosis warnings. (Not required to answer the infection-focused claim.)
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The described risks and management actions (avoid active serious infection; interrupt/discontinue for serious/opportunistic infection/sepsis; TB considerations; herpes zoster/viral reactivation; trial-reported infections) are consistent with the provided label sections.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement